Literature DB >> 21035946

Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.

Michelle L Varney1, Seema Singh, Aihua Li, Rosemary Mayer-Ezell, Richard Bond, Rakesh K Singh.   

Abstract

CXCR1 and CXCR2 are G-protein coupled receptors, that have been shown to play important role in tumor growth and metastasis, and are prime targets for the development of novel therapeutics. Here, we report that targeting CXCR2 and CXCR1 activity using orally active small molecule antagonist (SCH-527123, SCH-479833) inhibits human colon cancer liver metastasis mediated by decreased neovascularization and enhanced malignant cell apoptosis. There were no differences in primary tumor growth. These studies demonstrate the important role of CXCR2/1 in colon cancer metastasis and that inhibition of CXCR2 and CXCR1, small molecule antagonists provides a novel therapeutic strategy.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21035946      PMCID: PMC2994987          DOI: 10.1016/j.canlet.2010.10.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  47 in total

Review 1.  International union of pharmacology. XXII. Nomenclature for chemokine receptors.

Authors:  P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

2.  The "seed and soil" hypothesis revisited.

Authors:  Isaiah J Fidler; George Poste
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

3.  In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice.

Authors:  K Morikawa; S M Walker; J M Jessup; I J Fidler
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Authors:  Seema Singh; Anguraj Sadanandam; Kalyan C Nannuru; Michelle L Varney; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

Review 7.  The interleukin-8 pathway in cancer.

Authors:  David J J Waugh; Catherine Wilson
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 8.  CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing.

Authors:  Snjezana Zaja-Milatovic; Ann Richmond
Journal:  Histol Histopathol       Date:  2008-11       Impact factor: 2.303

Review 9.  A role for CXCR2 in senescence, but what about in cancer?

Authors:  Juan C Acosta; Jesús Gil
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 10.  The good and the bad of chemokines/chemokine receptors in melanoma.

Authors:  Ann Richmond; Jinming Yang; Yingjun Su
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-14       Impact factor: 4.693

View more
  59 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

Review 2.  The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions.

Authors:  Antonio Citro; Elisa Cantarelli; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

3.  Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines.

Authors:  Viktor A Adalsteinsson; Narmin Tahirova; Naren Tallapragada; Xiaosai Yao; Liam Campion; Alessandro Angelini; Thomas B Douce; Cindy Huang; Brittany Bowman; Christina A Williamson; Douglas S Kwon; K Dane Wittrup; J Christopher Love
Journal:  Integr Biol (Camb)       Date:  2013-10       Impact factor: 2.192

4.  High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients.

Authors:  Yu Zhu; Zheng Liu; Yiwei Wang; Hangcheng Fu; Zewei Wang; Huyang Xie; Junyu Zhang; Gaoxiang Li; Bo Dai; Dingwei Ye; Jiejie Xu
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

5.  Silencing of CXCR2 and CXCR7 protects against esophageal cancer.

Authors:  Kai Wu; Lingling Cui; Yang Yang; Jia Zhao; Dengyan Zhu; Donglei Liu; Chunyang Zhang; Yu Qi; Xiangnan Li; Weihao Li; Song Zhao
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

6.  High expression of CXCR-2 correlates with lymph node metastasis and predicts unfavorable prognosis in resected esophageal carcinoma.

Authors:  Ping Sui; Pingping Hu; Tiehong Zhang; Xiangwei Zhang; Qi Liu; Jiajun Du
Journal:  Med Oncol       Date:  2013-12-17       Impact factor: 3.064

Review 7.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit.

Authors:  Brian J Wilson; Karim R Saab; Jie Ma; Tobias Schatton; Pablo Pütz; Qian Zhan; George F Murphy; Martin Gasser; Ana Maria Waaga-Gasser; Natasha Y Frank; Markus H Frank
Journal:  Cancer Res       Date:  2014-06-16       Impact factor: 12.701

9.  CXCL8, IL-1β and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients.

Authors:  Betul Celik; Arzu Didem Yalcin; Gizem Esra Genc; Tangul Bulut; Sibel Kuloglu Genc; Saadet Gumuslu
Journal:  Biomed Rep       Date:  2016-06-30

10.  CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Authors:  Pierre Saintigny; Erminia Massarelli; Steven Lin; Young-Ho Ahn; Yulong Chen; Sangeeta Goswami; Baruch Erez; Michael S O'Reilly; Diane Liu; J Jack Lee; Li Zhang; Yuan Ping; Carmen Behrens; Luisa M Solis Soto; John V Heymach; Edward S Kim; Roy S Herbst; Scott M Lippman; Ignacio I Wistuba; Waun Ki Hong; Jonathan M Kurie; Ja Seok Koo
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.